Find a Clinical Trial
Is a clinical trial right for you? Search our database to find studies for which you may be eligible.
A Phase II Study of Ibrutinib Maintenance After Reduced-Intensity Conditioning and Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia
A Phase 2, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, PK, and Efficacy of Vimseltinib in Adults With Active Chronic GVHD After Failure of Prior Systemic Therapy
Study Type: Treatment
Phase: II
NCTID: NCT06619561
Principal Investigator:
Sunil Abhyankar
Long-Term Follow-up Study for Participants of Kite-Sponsored Interventional Studies Treated with Gene-Modified Cells
Study Type: Treatment
Phase: IV
NCTID: NCT05041309
Principal Investigator:
Nausheen Ahmed
Phase I/II Study of Donor-Derived Anti-CD33 Chimeric Antigen Receptor Expressing T Cells VCAR33 in Patients with Relapsed or Refractory Acute Myeloid Leukemia After Allogeneic Hematopoietic Cell Transplantation
Study Type: Treatment
Phase: I/II
NCTID: NCT05984199
Principal Investigator:
Muhammad Umair Mushtaq
A Phase II Study of Inotuzumab Ozogamicin Followed by Blinatumomab for Ph-Negative CD22-Positive B-Lineage Acute Lymphoblastic Leukemia in Newly Diagnosed Older Adults or Adults with Relapsed or Refractory Disease
A First-in-Human FIH, Phase 1, Multicenter, Open-label, Dose Escalation and Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Orally Administered GLB-001 in Patients with Refractory or Relapsed Acute Myeloid Leukemia R/R AML or Refractory or Relapsed Higher-risk Myelodysplastic Syndromes R/R HR-MDS
Study Type: Treatment
Phase: I
NCTID: NCT06146257
Principal Investigator:
Jesus Gonzalez Lugo
A Phase IB Study of the Anti-PD1 Antibody Pembrolizumab in Combination with the Histone Deacetylase Inhibitor, Entinostat for Treatment of Patients with Myelodysplastic Syndromes After DNA Methyltransferase Inhibitor Therapy Failure
A Comprehensive Approach to Improve Medication Adherence in Pediatric ALL
Study Type: Supportive Care
Phase: III
NCTID: NCT01503632
Principal Investigator:
Keith August
A Randomized Phase III Study of Bendamustine Plus Rituximab Versus Brutinib Plus Rituximab Versus Ibrutinib Alone in Untreated Older Patients 65 years of age with Chronic Lymphocytic Leukemia CLL
A Phase 3 Trial Investigating Blinatumomab NSC 765986 in Combination with Chemotherapy in Patients with Newly Diagnosed Standard Risk or Down Syndrome B-Lymphoblastic Leukemia B-ALL and the Treatment of Patients with Localized B-Lymphoblastic Lymphoma B-LLy
Study Type: Treatment
Phase: III
NCTID: NCT03914625
Principal Investigator:
Keith August